Ridloff Elena 4

What Happened

• Elena Ridloff, a director of Kymera Therapeutics (KYMR), exercised stock options to acquire 12,000 shares (7,400 on 2026-03-31 and 4,600 on 2026-04-01) at $14.18 per share (total exercise cost $170,160) and then sold all 12,000 shares in open‑market transactions for aggregate proceeds of approximately $1,024,661. The sales were effected at weighted-average prices of ~$85.37 (3/31) and ~$85.28 combined (4/1), producing a net inflow of roughly $854,501.
• These transactions appear to be a cashless exercise (exercise followed by immediate sale), which is commonly used to cover the exercise cost and taxes rather than a new bullish purchase.

Key Details

• Transaction dates: 2026-03-31 and 2026-04-01.
• Exercises (acquisitions): 7,400 shares @ $14.18 (3/31) and 4,600 shares @ $14.18 (4/1); total cost $170,160.
• Sales (dispositions): 7,400 shares @ weighted avg $85.37 (range $85.04–$85.64 per F2); 3,400 shares @ weighted avg ~$85.19 (part of range $85.00–$85.97 per F3); 1,200 shares @ $86.05 — total proceeds ≈ $1,024,661.
• Footnotes: Transactions were executed pursuant to a Rule 10b5‑1 trading plan dated December 11, 2025 (F1). Sale prices are reported as weighted averages with price ranges in F2 and F3. The options underlying the exercised shares were fully vested (F4).
• Shares owned after the transactions: not specified in the provided filing.
• Filing timeliness: Form 4 was filed 2026-04-01 for transactions on 3/31–4/01; no late filing indication in the record.

Context

• For retail investors: this is an option exercise immediately followed by sales (a cashless exercise), not a fresh buy signal. The use of a prearranged 10b5‑1 plan indicates the sales were planned in advance and are often routine.
• Derivative reporting: the Form 4 shows both the exercise (acquisition) and the conversion/disposition of the derivative (the option) for clarity — this is standard when options are exercised and the resulting shares are sold.